FDA Grants Approval for Levocarnitine ANDA217896 by Baxter Healthcare
The FDA has granted approval for the Abbreviated New Drug Application (ANDA) 217896 for Levocarnitine submitted by Baxter Healthcare.
Asset / Drug
Drug and asset intelligence for Levocarnitine with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.